Financial Daily from THE HINDU group of publications
Wednesday, Dec 22, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements


Ranbaxy gets FDA nod for hypertension drug

Our Bureau

New Delhi , Dec. 21

RANBAXY Laboratories Ltd has received approval from the US Food and Drug Administration (FDA) to manufacture and market Fosinopril Sodium and Hydrochlorothiazide tablets for the treatment of hypertension.

Ranbaxy's formulation was found to be bio-equivalent and with the same therapeutic effect as that of the reference-listed drug Monopril-HCT of Bristol-Myers Squibb. The total market sales for Monopril-HCT stood at $24.2 million.

"This final approval will allow Ranbaxy to offer the complete line of generic product formulations of Fosinopril to our customers and reflects our continued effort and commitment to supply affordable generic products to the market. The product will be made available immediately," said Mr Jim Meehan, Vice-President of Sales and Marketing for RPI, USA.

More Stories on : Announcements | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Ranbaxy gets FDA nod for hypertension drug


Coal India production target hiked to 332 mt
Lakshmi Overseas to pay 15 pc interim
Reliance Energy seeks to shift Anil's powers to RIL
Birlas' plea for Administrator over M.P. Birla estate resumes in HC
Zee Telefilms plans legal action against Padmalaya arm's chief
RIL borrows 116 m euros for expansion
`122 cos vanished after IPO in April `92-March `98'
Gulf Oil plans revamp of lubricants business
Natural Resources to expand capacity at 2 coke plants
HEC executes NCL order for electric rope shovels
BIFR gives time to promoters on Hindustan Cables' revival
`Change in urea pricing policy key to Madras Fert turnaround'
Widex India draws Rs 10-cr investment plan — To increase hearing aid dispensing centres
Top level changes in LG India
New MD of Keltec



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line